Cosentyx (Secukinumab) for Hidradenitis suppurativa | myHSteam

Connect with others who understand.

sign up Log in
About myHSteam
Powered By

Cosentyx is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe hidradenitis suppurativa (HS). Cosentyx is also known by its drug name, secukinumab.

Cosentyx is an immunomodulator — a drug that regulates the immune system’s activity. It’s considered a biologic disease-modifying antirheumatic drug (DMARD). Cosentyx is a genetically engineered antibody, or a protein the immune system uses to identify and neutralize substances. Cosentyx is believed to work by inhibiting interleukin 17A, a chemical messenger that researchers think is involved in HS inflammation.

How do I take it?
Cosentyx for HS is given every four weeks by subcutaneous injection (under the skin). It may be administered every two weeks if your body doesn’t respond well enough to the drug.

Cosentyx comes as a single-use pen or prefilled syringe.

Side effects
The FDA-approved label for Cosentyx lists common side effects including cold symptoms, upper respiratory tract infections, and diarrhea.

Rare but serious side effects listed for Cosentyx include severe infections, inflammatory bowel disease, and hypersensitivity reactions.

For more details about this treatment, visit:

Cosentyx — Novartis

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in